Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics

Metabolic health stories

Oct 30, 2026

University of Copenhagen study finds vegans have lower gut bacterial diversity than omnivores

A new study from the University of Copenhagen reveals that vegans unexpectedly have less diverse gut bacteria compared to omnivores, with lower protein intake potentially explaining the difference. The findings challenge assumptions about how plant-based diets affect the gut microbiome ecosystem.

Oct 30, 2026·2 sources
00

European researchers develop blood test using ten markers to assess healthy aging and disease risk

Researchers led by Joris Deelen have created a personalized metabolic indicator that uses ten blood markers to provide a detailed snapshot of a patient's metabolism, aimed at promoting healthy aging and reversing the trend of chronic conditions affecting 60% of people over age 65.

Oct 30, 2026·2 sources
00
Oct 29, 2026

Major international studies identify accurate non-invasive tests for metabolic liver disease

Two major international studies have delivered the strongest evidence to date on which non-invasive tests can accurately diagnose and measure the severity of metabolic dysfunction-associated steatotic liver disease (MASLD) and its more severe form, MASH, potentially reducing reliance on liver biopsy.

Oct 29, 2026·3 sources
00
Oct 19, 2026

University of Barcelona identifies ENT1 protein as potential treatment target for fatty liver disease

Researchers at the University of Barcelona have discovered that the protein ENT1, which transports small molecules, plays a key role in the development of metabolic dysfunction-associated steatotic liver disease (MASLD), the world's most common chronic liver disease. The finding could lead to new treatment approaches for the condition.

Oct 19, 2026·1 source
00

Study finds nearly three-quarters of bariatric surgery candidates meet new clinical obesity criteria

A new study examining adults undergoing metabolic bariatric surgery at four centers found that nearly 3 in 4 candidates had clinical obesity, a phenotype that BMI measurements alone could not distinguish from preclinical obesity.

Oct 19, 2026·1 source
00
Oct 18, 2026

Study links Neu5Gc sugar in red meat to 63% higher type 2 diabetes risk

A study of nearly 90,000 adults found that people consuming the most Neu5Gc, a sugar naturally present in red meat, had a 63% higher risk of developing type 2 diabetes. Scientists suspect the sugar may trigger chronic inflammation, potentially revealing a hidden mechanism behind the long-observed connection between red meat consumption and diabetes.

Oct 18, 2026·2 sources
00
Oct 14, 2026

GLP-1 drugs reduce psychiatric hospital visits in schizophrenia patients with diabetes

A large US health records study found that people with schizophrenia taking GLP-1 drugs for diabetes had fewer psychiatric relapses and hospital admissions, suggesting potential mental health benefits beyond metabolic effects.

Oct 14, 2026·2 sources
00
Oct 9, 2026

Late-night eating linked to 20-30% higher risk of liver disease, OHSU study finds

A large study led by Oregon Health & Science University analyzing data from nearly 200,000 people found that eating late at night or after dinner is associated with a 20% to 30% increased risk of liver disease, including fatty liver disease and cirrhosis. The research, published in Clinical Gastroenterology and Hepatology, suggests meal timing may be an important factor in liver health beyond caloric intake.

Oct 9, 2026·6 sources
00
Oct 7, 2026

Zealand Pharma and Roche's amylin drug achieves 9.2% weight loss in Phase 2 trial

Zealand Pharma and Roche reported that their experimental amylin drug helped patients with type 2 diabetes lose up to 9.2% of body weight in a mid-stage trial, as they seek to compete with Eli Lilly in the obesity and diabetes market.

Oct 7, 2026·2 sources
00

Zealand Pharma's petrelintide shows 9.2% weight loss in Phase 2 obesity trial

Zealand Pharma announced positive Phase 2 ZUPREME-2 trial results for its amylin analog petrelintide, which achieved up to 9.2% mean body weight reduction at week 28 versus 2.0% with placebo in people with overweight or obesity and type 2 diabetes. The drug also demonstrated HbA1c reduction of up to 0.65% versus an increase of 0.23% with placebo.

Oct 7, 2026·3 sources
00
Oct 2, 2026

Retatrutide shows substantial weight loss in type 2 diabetes patients in phase III trial

The investigational triple agonist retatrutide demonstrated significant weight loss and improved glycemic control in adults with obesity and type 2 diabetes in the TRIUMPH-2 phase III trial, with some participants losing up to a quarter of their body weight. Results were presented at the European Association for the Study of Diabetes annual meeting in Milan and published in The Lancet.

Oct 2, 2026·5 sources
00
Sep 30, 2026

Eli Lilly's amylin-Zepbound combination shows record 23% weight loss in diabetes trial

Eli Lilly reported that its experimental combination of amylin drug eloraTZP with Zepbound (tirzepatide) achieved up to 23% weight loss in patients with type 2 diabetes and obesity, outperforming Zepbound alone and representing the highest weight loss seen in similar studies to date.

Sep 30, 2026·6 sources
00

Regeneron weight-loss drug halves muscle loss when combined with semaglutide

An experimental weight-loss drug from Regeneron reduced muscle mass loss by 50% when used in combination with Novo Nordisk's semaglutide, compared to semaglutide alone, according to trial results presented at a medical meeting.

Sep 30, 2026·2 sources
00
Sep 29, 2026

Enzyme UBE2N identified as potential defense against fatty liver disease progression

Researchers at Cedars-Sinai have identified an enzyme called UBE2N that may help protect the liver from damage as fatty liver disease worsens. The enzyme helps liver cells clear damaged mitochondria and break down fat, potentially preventing inflammation and progression toward liver failure in a condition affecting an estimated 100 million Americans.

Sep 29, 2026·4 sources
00
Sep 22, 2026

Roche's obesity drug enicepatide cuts body weight 15.5% in mid-stage trial

Roche's experimental obesity shot enicepatide reduced blood sugar and body weight by 15.5% in type-2 diabetes patients in a mid-stage trial, with a meaningful proportion reaching normalized glucose levels within less than a year of treatment.

Sep 22, 2026·2 sources
00
Sep 17, 2026

FDA approves finerenone for chronic kidney disease in type 1 diabetes

The FDA approved finerenone (Kerendia) for treating chronic kidney disease associated with type 1 diabetes, marking the first new drug approval for this indication in decades.

Sep 17, 2026·2 sources
00
Aug 28, 2026

Keto diet reduced liver fat by 67% in clinical trial

A ketogenic diet outperformed Mediterranean and low-fat diets in reducing liver fat and improving metabolic health markers in a clinical trial of people with obesity, prediabetes, and fatty liver disease.

Aug 28, 2026·2 sources
00
Aug 24, 2026

Roche gains rights to Hanmi obesity drug that preserves muscle mass

Roche acquired rights to Hanmi Pharmaceutical's obesity drug for $190 million upfront and up to $2.3 billion total. The drug is designed to activate receptors in skeletal muscle to increase muscle mass while reducing fat, addressing a key concern with current GLP-1 weight loss medications.

Aug 24, 2026·2 sources
00
Aug 18, 2026

Amylyx drug avexitide reduces severe low blood sugar episodes in post-bariatric surgery patients

Amylyx Pharmaceuticals' experimental drug avexitide met its primary endpoint in a Phase 3 trial for post-bariatric hypoglycemia, showing a 55% reduction in serious low blood sugar events compared to placebo in patients who experienced dangerously low blood sugar following weight-loss surgery.

Aug 18, 2026·2 sources
00
Aug 12, 2026

AI tools being developed to detect fatty liver disease affecting over 1 billion people globally

Researchers are developing artificial intelligence tools to detect fatty liver disease early, as the condition affects over a billion people worldwide and is increasingly appearing in young adults, particularly in countries like India where metabolic diseases are rising among people in their 20s.

Aug 12, 2026·2 sources
00
Aug 6, 2026

Study Finds Polyethylene Microplastics in Food Packaging May Worsen Fatty Liver Disease

New research reveals that polyethylene, one of the world's most widely used plastics found in food packaging, may increase the risk of fatty liver disease by disrupting the liver's natural repair mechanisms. The finding is surprising because polyethylene has long been considered biologically inert.

Aug 6, 2026·5 sources
00
Aug 1, 2026

Eating less protein may slow aging and improve metabolism, major review finds

A comprehensive review of over 350 studies suggests that consuming less protein than currently popular may improve metabolism, reduce inflammation, and potentially slow aging processes.

Aug 1, 2026·1 source
00
Jul 24, 2026

Stanford researchers use AI to discover naturally occurring molecule BRP that mimics Ozempic without common side effects

Stanford Medicine scientists have identified a naturally occurring peptide called BRP that suppresses appetite and reduces body weight in animal studies, potentially offering similar benefits to drugs like Ozempic and Wegovy but without side effects such as nausea, digestive issues, and muscle loss. The molecule was discovered using artificial intelligence algorithms.

Jul 24, 2026·5 sources
00
Jul 21, 2026

New Study Finds Women with PMOS Face Quadruple Risk of Heart Disease and Stroke

A major study published in The Lancet analyzing 2.5 million U.S. women found that those with polyendocrine metabolic ovarian syndrome (PMOS, formerly PCOS) have four times the risk of cardiovascular disease, including heart attacks and strokes, compared to women without the condition.

Jul 21, 2026·8 sources
00
Jul 17, 2026

India approves Wegovy for fatty liver disease treatment

India's drug regulator approved Novo Nordisk's obesity drug Wegovy for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease, expanding the drug's approved uses beyond weight loss.

Jul 17, 2026·1 source
00
Jul 14, 2026

Semaglutide may slow biological aging in adults with HIV

Researchers found that semaglutide, the active ingredient in Ozempic and Wegovy, slowed biological aging markers in adults with HIV, marking the first clinical evidence that the drug may influence human aging beyond its metabolic effects.

Jul 14, 2026·1 source
00
Jul 13, 2026

Losing 80 minutes of sleep nightly causes weight gain and reduced activity

Six-week study found that sleeping approximately 80 minutes less per night caused participants to gain weight and spend more time inactive, demonstrating effects of realistic mild sleep loss.

Jul 13, 2026·1 source
00
May 21, 2026

Eli Lilly's Retatrutide Achieves Up to 30% Weight Loss in Phase 3 TRIUMPH-1 Trial

Eli Lilly announced positive results from its Phase 3 TRIUMPH-1 trial showing retatrutide, an experimental triple-agonist obesity drug, achieved average weight loss of 28.3% at 80 weeks and 30.3% at 104 weeks on the highest dose, matching weight reduction levels typically seen with bariatric surgery.

May 21, 2026·3 sources
00
May 12, 2026

Polycystic Ovary Syndrome Renamed to Polyendocrine Metabolic Ovarian Syndrome After Global Consensus

After more than a decade of discussion, polycystic ovary syndrome (PCOS) has been officially renamed polyendocrine metabolic ovarian syndrome (PMOS) through a global consensus process involving patients and clinicians. The change affects a condition impacting approximately 170 million women worldwide and is expected to improve diagnosis and treatment.

May 12, 2026·8 sources
00

Polycystic Ovary Syndrome Renamed to Polyendocrine Metabolic Ovarian Syndrome After Decade of Debate

A global consortium of healthcare experts has officially renamed Polycystic Ovary Syndrome (PCOS) to Polyendocrine Metabolic Ovarian Syndrome (PMOS), a change affecting over 170 million women worldwide. Health experts say the new name better reflects the condition's systemic nature and is expected to improve diagnosis and treatment.

May 12, 2026·6 sources
00
May 3, 2026

Stopping and Restarting GLP-1 Weight Loss Drugs May Reduce Their Effectiveness

Preclinical study from University of Pennsylvania researchers finds that inconsistent use of GLP-1 medications like Ozempic and Wegovy may significantly lessen their effectiveness for weight loss.

May 3, 2026·1 source
00
May 2, 2026

Vegan Diet Outperforms Mediterranean Diet on Emissions and Metabolic Health in Randomized Trial

A randomized clinical trial found that a vegan diet produced better outcomes than a Mediterranean diet for both metabolic health markers and environmental emissions, providing clear evidence linking dietary choices to human and planetary health.

May 2, 2026·1 source
00
Apr 29, 2026

Bariatric Surgery Shows Greater Long-Term Cardiovascular Benefits Than GLP-1 Weight-Loss Medications

Mayo Clinic study finds metabolic and bariatric surgery provides significantly greater long-term cardiovascular risk reduction compared to GLP-1 medications in people with obesity, despite both treatments improving heart health.

Apr 29, 2026·1 source
00
Apr 18, 2026

Weight Loss Medications Lead to Notable Muscle Loss Alongside Fat Loss

UNC School of Medicine study finds incretin-based medications including semaglutide and tirzepatide cause significant muscle loss in addition to fat reduction, raising concerns about long-term metabolic effects.

Apr 18, 2026·1 source
00
Apr 17, 2026

Scientists Behind GLP-1 Obesity Drugs Propose Dropping GLP-1 as Target

Researchers who developed GLP-1 obesity medications are now advancing a provocative hypothesis that targeting the GLP-1 hormone may not be necessary for effective weight loss, potentially reshaping the approach to obesity treatment.

Apr 17, 2026·2 sources
00
Apr 13, 2026

Genetic Variants Explain Why GLP-1 Drugs Like Ozempic Don't Work for 10% of Patients

New research reveals that approximately 10% of people carry specific genetic variants that make popular diabetes and weight-loss drugs like Ozempic and Wegovy significantly less effective, providing the first genetic explanation for variable drug response.

Apr 13, 2026·1 source
00
Apr 9, 2026

Study Links $35 Insulin Cap to Improved Treatment Adherence in Type 2 Diabetes

Research demonstrates that capping insulin costs at $35 per month significantly improves medication adherence among patients with type 2 diabetes, providing evidence for price control policies.

Apr 9, 2026·1 source
00
Apr 8, 2026

23andMe Identifies Genetic Variants Predicting GLP-1 Drug Response and Side Effects

Research from 23andMe found that changes in two genes appear to help predict whether patients will lose substantial weight on GLP-1 drugs and whether they will experience nausea or vomiting.

Apr 8, 2026·1 source
00

Top claims

  • ▪A study by University of Copenhagen researchers published in Microbiome examined 75 vegans and 75 omnivorous Danes and found that gut bacterial diversity was, on average, lower among vegans than omnivores.
  • ▪Professor Oluf Borbye Pedersen noted that the study is observational and cannot establish whether protein intake directly causes changes in gut bacterial biodiversity.
  • ▪The study by University of Copenhagen researchers found that gut bacterial diversity in vegans was unexpectedly lower despite vegans consuming higher amounts of dietary fiber and health-promoting plant compounds.

Subtopics

Lifestyle, Wellness and Nutrition16Weight management16Drug Approval and Clinical Trials13Drug Policy, Pricing & Approval13GLP-1 medications11Weight loss medications & GLP-1 drugs11Biomarkers & bloodwork testing7Clinical trials7GLP-1 / Weight-Loss Medications6Nutrition fundamentals6Blood sugar & insulin5Diet & nutrition4Longevity & aging4Obesity treatment4Pharma4AI research & benchmarks2Chronic disease2Dietary patterns2Drug development2Eli Lilly2GLP-12Inflammation reduction & immune effects2Longevity & biohacking2Mediterranean diet2

Related timelines

Congress

110 stories

Crypto hacks

100 stories

Iran War

209 stories

Payments

118 stories

Russia-Ukraine war

136 stories